Please assess the completion status of the following clinical trial:

Trial Title: Safety of FCM vs. Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female with iron deficiency anemia~* Hg \</= 11 g/dL~Exclusion Criteria:~* Previous participation in a FCM trial~* Known Hypersensitivity to FCM~* History of anemia other that anemia due to heavy uterine bleeding or the post partum state~* current history of GI bleeding~* Received IV Iron within the month prior~* Anticipated need for surgery~* Malignancy history~* AST or ALT greater than normal~* Received an investigational drug within 30 days of screening~* Pregnant or sexually active females who are not willing ot use an effective form of birth control

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ferric Carboxymaltose (FCM) (Type: EXPERIMENTAL): Undiluted dose of iron as FCM IV (15 mg/kg up to a maximum of 1000 mg)
- Standard Medical Care (SMC) (Type: ACTIVE_COMPARATOR): Varied as determined by the Investigator

Based on this trial design, predict the completion outcome and termination type (if applicable).